Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of SENS-401 for the Treatment of Sudden Sensorineural Hearing Loss (or SSNHL) in Pediatric Population

X
Trial Profile

A Phase II Trial of SENS-401 for the Treatment of Sudden Sensorineural Hearing Loss (or SSNHL) in Pediatric Population

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arazasetron (Primary)
  • Indications Sensorineural hearing loss
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Sensorion
  • Most Recent Events

    • 10 May 2024 Status changed from planning to completed.
    • 19 Jun 2023 According to a Sensorion media release, SENS-401 has been granted Orphan Drug Designation by the EMA in Europe for the treatment of sudden sensorineural hearing loss, and by the FDA in the U.S. for the prevention of platinum-induced ototoxicity in pediatric population.
    • 06 Jul 2020 According to a Sensorion media release, data expected in mid-2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top